Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancer

Väisänen,Marja-Riitta; Jukkola-Vuorinen,Arja; Vuopala,Katri  S.; Selander,Katri  S.; Vaarala,Markku  H.

doi:10.3892/ol.2013.1204

Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancer

Authors:
- Marja-Riitta Väisänen
- Arja Jukkola-Vuorinen
- Katri S. Vuopala
- Katri S. Selander
- Markku H. Vaarala
View Affiliations

Affiliations: Department of Pathology, Oulu University Hospital, 90029 OYS, Finland, Department of Oncology, Oulu University Hospital, 90029 OYS, Finland, Department of Pathology, Lapland Central Hospital, 96101 Rovaniemi, Finland, Department of Medicine, Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL 35294‑2182, USA, Department of Surgery, Oulu University Hospital, 90029 OYS, Finland
Published online on: February 20, 2013 https://doi.org/10.3892/ol.2013.1204
Pages: 1659-1663

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Toll-like receptor-9 (TLR9) is a member of the innate immune system and recognizes bacterial and vertebrate DNA in cells. In addition to being expressed in cells of the immune system, it is widely expressed in various types of human cancer, including prostate cancer. We have previously demonstrated that synthetic TLR9 ligands induce invasion in TLR9-expressing prostate cancer cells in vitro. However, the role of TLR9 in the pathophysiology of prostate cancer is unclear. The expression of TLR9 in radical prostatectomy samples (n=186) was studied using immunohistochemistry. TLR9 staining scores were compared with tumor stage, Gleason score and prostate-specific antigen (PSA) concentration prior to treatment and progression-free survival. Results revealed that 124 (66.7%) of the tumors were strongly positive, 59 (31.7%) were weakly positive and 3 (1.6%) were negative, for cytoplasmic TLR9 immunostaining in cancer cells. There was no significant association between cytoplasmic TLR9 expression and distributions of pT-class, prostatectomy sample margin status, Gleason score and preoperative PSA value. Prostate cancer-specific progression-free survival was significantly longer for patients whose tumors were graded as negative for cytoplasmic TLR9 expression, as compared with patients whose tumors were strongly immunopositive for cytoplasmic TLR9 (P=0.009). In the Cox regression analysis, high TLR9 expression was an independent marker of poor prognosis in prostate cancer. Expression of TLR9 is associated with poor progression-free survival in prostate cancer patients who were treated by radical prostatectomy with curative intent.

View Figures

View References

1	Jinushi M: The role of innate immune signals in antitumor immunity. Oncoimmunology. 1:189–194. 2012. View Article : Google Scholar : PubMed/NCBI
2	Akira S and Hemmi H: Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 85:85–95. 2003. View Article : Google Scholar : PubMed/NCBI
3	Hidmark A, von Saint Paul A and Dalpke AH: Cutting edge: TLR13 Is a Receptor for Bacterial RNA. J Immunol. 189:2717–2721. 2012. View Article : Google Scholar : PubMed/NCBI
4	Chang YJ, Wu MS, Lin JT and Chen CC: Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol. 175:8242–8252. 2005. View Article : Google Scholar
5	Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P and Goldmann T: Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res. 6:12005. View Article : Google Scholar : PubMed/NCBI
6	Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW and Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 4:437–447. 2006. View Article : Google Scholar : PubMed/NCBI
7	Takala H, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP, Saarnio J and Karttunen TJ: Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun. 3:631–638. 2011. View Article : Google Scholar : PubMed/NCBI
8	Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J and Karttunen TJ: Increased Toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma. Histopathology. 59:643–649. 2011. View Article : Google Scholar : PubMed/NCBI
9	Väisänen MR, Väisänen T, Jukkola-Vuorinen A, Vuopala KS, Desmond R, Selander KS and Vaarala MH: Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate. 70:817–824. 2010.PubMed/NCBI
10	Ronkainen H, Hirvikoski P, Kauppila S, Vuopala KS, Paavonen TK, Selander KS and Vaarala MH: Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J Exp Clin Cancer Res. 30:842011. View Article : Google Scholar : PubMed/NCBI
11	Jukkola-Vuorinen A, Rahko E, Vuopala KS, Desmond R, Lehenkari PP, Harris KW and Selander KS: Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer. J Innate Immun. 1:59–68. 2008. View Article : Google Scholar : PubMed/NCBI
12	Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW and Selander KS: Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate. 67:774–781. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, Zhou Y, Zhou H and Wen Z: TLR9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res. 15:623–630. 2009. View Article : Google Scholar : PubMed/NCBI
14	Sandholm J, Kauppila JH, Pressey C, Tuomela J, Jukkola-Vuorinen A, Vaarala M, Johnson MR, Harris KW and Selander KS: Estrogen receptor-alpha and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells. Breast Cancer Res Treat. 132:411–419. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y and Guise TA: Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem. 277:24571–24578. 2002. View Article : Google Scholar
16	Flatt T, Heyland A, Rus F, Porpiglia E, Sherlock C, Yamamoto R, Garbuzov A, Palli SR, Tatar M and Silverman N: Hormonal regulation of the humoral innate immune response in Drosophila melanogaster. J Exp Biol. 211:2712–2724. 2008. View Article : Google Scholar : PubMed/NCBI
17	Tuomela J, Sandholm J, Karihtala P, Ilvesaro J, Vuopala KS, Kauppila JH, Kauppila S, Chen D, Pressey C, Harkonen P, Harris KW, Graves D, Auvinen PK, Soini Y, Jukkola-Vuorinen A and Selander KS: Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat. 135:481–493. 2012. View Article : Google Scholar : PubMed/NCBI
18	Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trepo C, Hasan U and Chemin I: Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One. 6:e263152011. View Article : Google Scholar : PubMed/NCBI
19	Yu SL, Chan PK, Wong CK, Szeto CC, Ho SC, So K, Yu MM, Yim SF, Cheung TH, Wong MC, Cheung JL, Yeung AC, Li EK and Tam LS: Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus. Arthritis Res Ther. 14:R802012. View Article : Google Scholar : PubMed/NCBI
20	González-Reyes S, Fernandez JM, González LO, Aguirre A, Suarez A, González JM, Escaff S and Vizoso FJ: Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother. 60:217–226. 2011.PubMed/NCBI
21	Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW and Selander KS: Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res. 6:1534–1543. 2008. View Article : Google Scholar : PubMed/NCBI
22	Nakai Y and Nonomura N: Inflammation and prostate carcinogenesis. Int J Urol. Jul 31–2012.(Epub ahead of print). View Article : Google Scholar
23	Kundu SD, Lee C, Billips BK, Habermacher GM, Zhang Q, Liu V, Wong LY, Klumpp DJ and Thumbikat P: The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate. 68:223–229. 2008. View Article : Google Scholar : PubMed/NCBI
24	Di JM, Pang J, Sun QP, Zhang Y, Fang YQ, Liu XP, Zhou JH, Ruan XX and Gao X: Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF-kappaB in prostate cancer cells. Mol Biol Rep. 37:1849–1855. 2010. View Article : Google Scholar : PubMed/NCBI
25	Di JM, Pang J, Pu XY, Zhang Y, Liu XP, Fang YQ, Ruan XX and Gao X: Toll-like receptor 9 agonists promote IL-8 and TGF-beta1 production via activation of nuclear factor kappaB in PC-3 cells. Cancer Genet Cytogenet. 192:60–67. 2009. View Article : Google Scholar : PubMed/NCBI